Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies.

According to a release, the study will take place in up to 15 centers in the United States for patients with a variety of orphan-designated relapse or refractory hematologic cancers.

“I would like to thank the entire team at Cellectar whose diligent efforts enabled the company to initiate the Phase II trial a full quarter ahead of our original guidance,” Cellectar Biosciences CEO Jim Caruso said in a statement. “Given the results from our Phase I trial of CLR 131 in multiple myeloma, we are enthusiastic about the potential outcomes of this Phase II trial, and look forward to reporting results as they become available.”

Initial data from the study is expected as early as the second half of 2017.